Alnylam Pharmaceuticals has surpassed a market capitalization of $50 billion following a robust launch of Amvuttra, its RNA interference therapy for transthyretin amyloidosis cardiomyopathy (ATTR-CM). The drug's Q2 sales more than doubled year-over-year, significantly exceeding analyst expectations. Uptake has been broad across both first-line and stabilizer-progressing patients, with widespread coverage across major health systems, positioning Amvuttra as a leader in its therapeutic category.